Search filters

Filters
Clear All

Phase

  • 4
  • 7
  • 7
  • 6
  • 26
  • 18
  • 1
  • 25

Found 26 Multiple Myeloma trials

A listing of Multiple Myeloma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

99 years or below
All genders
Phase 1
This is a Phase 1, first-in-human, multicenter; non-randomized, open-label and dose escalation study of AMG 176 administered IV in subjects with relapsed or refractory multiple myeloma and subjects with relapsed or refractory AML.
 Long-term Follow-up Study for Participants Previously Treated with Ciltacabtagene Autoleucel
18 years - 99 years
All genders
Interventional
Participants invited to participate in a research study must have diagnosis of multiple myeloma and have been previously treated with the study drug, cilta-cel. The purpose of this research is to monitor the health status of subjects who were previously enrolled in cilta-cel.
99 years or below
All genders
Phase 2
The purpose of this study is to test the safety of an experimental drug CC-220, alone and in combination with other treatments. The study is also designed to define the appropriate dose for further testing of the study drug and these experimental combinations.
 Phase I Study of Tasquinimod Alone and in Combination with Standard Therapy for Relapsed or Refractory Myeloma
99 years or below
All genders
Phase 1
The research study is being conducted to understand the effects of tasquinimod, an experimental medication, on patients with myeloma. Eligibile subject have multiple myeloma that has been previously treated and is now in need of additional treatment. Part 1 of this study evaluates tasquinimod alone. Part 2 of this study …
 Multicenter Interventional Lymphangioleiomyomatosis Early Disease Trial (MILED Trial)
99 years or below
All genders
This application is a request to execute a reliance agreement with the Cincinnati Children's Hospital Medical Center (CCHMC) IRB.
 Expanded Access Protocol (Eap) For Subjects Receiving Idecabtagene Vicleucel That Is Nonconforming
18 years - 99 years
All genders
Observational
This study is designed to provide patients access to their nonconforming ide-cel as a treatment option for their disease. The study will evaluate the safety and effectiveness of this therapy through the collection of information. You may or may not receive direct medical benefit from participating in this study. The …
21 - 26 of 26